PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results
07 August 2023 - 10:00PM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing a growing pipeline of targeted
cancer immunotherapies and infectious disease vaccines based on the
Company’s proprietary T cell activating platforms, today announced
that the Company will release financial results for the second
quarter of 2023 on Monday, August 14, 2023, before the market
opens. Following the release, management will host a conference
call to review the financial results and provide a business update.
Monday, August 14, 2023, 8:00 AM
ET Domestic: 877-407-3088International: 201-389-0927
Conference ID: 13739270 Webcast: PDS Biotech Earnings
Webcast
After the live webcast, the event will be
archived on PDS Biotech’s website for six months.
About PDS
Biotechnology PDS Biotech is a
clinical-stage immunotherapy company developing a growing pipeline
of targeted cancer and infectious disease immunotherapies based on
our proprietary Versamune®, Versamune® plus PDS0301, and
Infectimune® T cell-activating platforms. We believe our targeted
immunotherapies have the potential to overcome the limitations of
current immunotherapy approaches through the activation of the
right type, quantity and potency of T cells. To date, our lead
Versamune® clinical candidate, PDS0101, has demonstrated the
ability to reduce and shrink tumors and stabilize disease in
combination with approved and investigational therapeutics in
patients with a broad range of HPV16-associated cancers in multiple
Phase 2 clinical trials and will be advancing into a Phase 3
clinical trial in combination with KEYTRUDA® for the treatment of
recurrent/metastatic HPV16-positive head and neck cancer in 2023.
Our Infectimune® based vaccines have also demonstrated the
potential to induce not only robust and durable neutralizing
antibody responses, but also powerful T cell responses, including
long-lasting memory T cell responses in pre-clinical studies to
date. To learn more, please visit www.pdsbiotech.com or follow us
on Twitter at @PDSBiotech.
Investor Contacts:Deanne
RandolphPDS BiotechPhone: +1 (908) 517-3613Email:
drandolph@pdsbiotech.com
Rich CockrellCG CapitalPhone: +1 (404)
736-3838Email: pdsb@cg.capital
Media Contacts: Tiberend
Strategic Advisors, Inc.Dave Schemelia Phone: +1 (609)
468-9325 dschemelia@tiberend.com
Eric ReissPhone: +1 (802)
249-1136ereiss@tiberend.com
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Apr 2024 to May 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From May 2023 to May 2024